Buprenorphine is an opioid used to treat opioid addiction, acute pain, and chronic pain. It can be used under the tongue, by injection, as a skin patch, or as an implant. For opioid addiction it is typically only started when withdrawal symptoms have begun and for the first two days of treatment under direct observation of a health care provider. The aim of the present study was to develop buccal formulation of buprenorphine to maintain constant therapeutic levels of the drug for over 12 hrs. Various grades of HPMC were employed as polymers. Buprenorphine dose was fixed as 8 mg. Total weight of the tablet was considered as 100 mg. Polymers were used in the concentration of 4 mg, 8mg and 12 mg concentration. All the formulations were passed various physicochemical evaluation parameters and they were found to be within limits. Whereas from the dissolution studies it was evident that the formulation (F8) showed better and desired drug release pattern i.e.,98.54 % in 12 hours. It followed Peppas release kinetics mechanism.
